Related Experiment Videos
Ketoconazole treatment of nail infection in chronic mucocutaneous candidiasis
Abstract:
Chronic mucocutaneous candidiasis is an immunodeficiency disorder which has significant morbidity due to mucous membrane, skin and nail infection. Attempts at reconstitution of immunological abnormalities have had only limited success. Ketoconazole is a newly available oral antifungal agent with activity against candida species. Prolonged administration of ketoconazole to four children with chronic mucocutaneous candidiasis caused marked improvement at infected sites. Resolution of nail infections took up to 12 months.
Insights
Chronic mucocutaneous candidiasis, an immunodeficiency disorder, showed marked improvement in children treated with oral ketoconazole. This antifungal agent effectively treated skin, mucous membrane, and nail infections, though nail resolution took up to a year.
Area of Science:
- Immunology
- Mycology
- Dermatology
Background:
- Chronic mucocutaneous candidiasis is an immunodeficiency disorder causing significant morbidity from infections of mucous membranes, skin, and nails.
- Previous attempts to correct immunological abnormalities in this condition have yielded limited success.
Observation:
- Ketoconazole, a new oral antifungal, demonstrates activity against Candida species.
- Four children with chronic mucocutaneous candidiasis received prolonged administration of ketoconazole.
Findings:
- Marked improvement was observed at infected sites in all four children.
- Complete resolution of nail infections required up to 12 months of treatment.
Implications:
- Oral ketoconazole represents a promising therapeutic option for chronic mucocutaneous candidiasis.
- The prolonged treatment duration required for nail infections highlights the persistent nature of the condition.